Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/β-catenin signaling

Oncogene

Volumn 34, Issue 31, 2015, Pages 4089-4097

  Bai, X L ^a   Zhang, Q ^a   Ye, L Y ^a   Liang, F ^a   Sun, X ^c   Chen, Y ^b   Hu, Q D ^a   Fu, Q H ^a   Su, W ^a   Chen, Z ^c   Zhuang, Z P ^d   Liang, T B ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CHILDREN S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CD31 ANTIGEN; GELATINASE B; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOCYTE ENHANCER FACTOR 2; PROTEIN KINASE C; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; WNT PROTEIN; MEF2C PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CANCER GROWTH; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; DEACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; ANIMAL; BAGG ALBINO MOUSE; DISEASE COURSE; GENETICS; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ANIMALS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; MALE; MEF2 TRANSCRIPTION FACTORS; MICE; MICE, INBRED BALB C; MICE, NUDE; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WNT SIGNALING PATHWAY;

EID: 84938504101     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.337     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Potthoff MJ, Olson EN. MEF2: a central regulator of diverse developmental programs. Development 2007; 134: 4131-4140.
3. Homminga I, Pieters R, Langerak AW, de Rooi JJ, Stubbs A, Verstegen M et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 2011; 19: 484-497.
4. Li BQ, Huang T, Liu L, Cai YD, Chou KC. Identification of colorectal cancer related genes with mRMR and shortest path in protein-protein interaction network. PLoS ONE 2012; 7: e33393.
5. Zhang JJ, Zhu Y, Xie KL, Peng YP, Tao JQ, Tang J et al. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in MUC4/ErbB2/p38/MEF2C-dependent mechanism. Mol Cancer 2014; 13: 130.
6. Bai X, Wu L, Liang T, Liu Z, Li J, Li D et al. Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134: 83-91.
7. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004; 56: 549-580.
8. Maiti D, Xu Z, Duh EJ. Vascular endothelial growth factor induces MEF2C and MEF2-dependent activity in endothelial cells. Invest Ophthalmol Vis Sci 2008; 49: 3640-3648.
9. Lin Q, Lu J, Yanagisawa H, Webb R, Lyons GE, Richardson JA et al. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 1998; 125: 4565-4574.
10. Xu J, Cao S, Wang L, Xu R, Chen G, Xu Q. VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C. PLoS ONE 2011; 6: e27165.
11. Bi W, Drake CJ, Schwarz JJ. The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expression of angiopoietin and VEGF. Dev Biol 1999; 211: 255-267.
12. Shang Y, Doan CN, Arnold TD, Lee S, Tang AA, Reichardt LF et al. Transcriptional corepressors HIPK1 and HIPK2 control angiogenesis via TGF-beta-TAK1-dependent mechanism. PLoS Biol 2013; 11: e1001527.
13. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology 2012; 142: 219-232.
14. Zhang Q, Bai X, Chen W, Ma T, Hu Q, Liang C et al. Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis 2013; 34: 962-973.
15. Saint Just Ribeiro M, Hansson ML, Lindberg MJ, Popko-Scibor AE, Wallberg AE. GSK3beta is a negative regulator of the transcriptional coactivator MAML1. Nucleic Acids Res 2009; 37: 6691-6700.
16. Riazi AM, Takeuchi JK, Hornberger LK, Zaidi SH, Amini F, Coles J et al. NKX2-5 regulates the expression of beta-catenin and GATA4 in ventricular myocytes. PLoS ONE 2009; 4: e5698.
17. De Angelis L, Borghi S, Melchionna R, Berghella L, Baccarani-Contri M, Parise F et al. Inhibition of myogenesis by transforming growth factor beta is density-dependent and related to the translocation of transcription factor MEF2 to the cytoplasm. Proc Natl Acad Sci USA 1998; 95: 12358-12363.
18. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579-591.
19. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol 2012; 181: 1115-1125.
20. Kirschmann DA, Seftor EA, Hardy KM, Seftor RE, Hendrix MJ. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 2012; 18: 2726-2732.
21. Goel HL, Mercurio AM. VEGF targets the tumor cells. Nat Rev Cancer 2013; 13: 871-882.
22. Zhou L, Wang DS, Li QJ, Sun W, Zhang Y, Dou KF. Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor. Oncol Rep 2012; 28: 874-882.
23. Maatta M, Soini Y, Liakka A, Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 2000; 6: 2726-2734.
24. Chen SL, Wang SC, Hosking B, Muscat GE. Subcellular localization of the steroid receptor coactivators (SRCs) and MEF2 in muscle and rhabdomyosarcoma cells. Mol Endocrinol 2001; 15: 783-796.
25. Borghi S, Molinari S, Razzini G, Parise F, Battini R, Ferrari S. The nuclear localization domain of the MEF2 family of transcription factors shows member-specific features and mediates the nuclear import of histone deacetylase 4. J Cell Sci 2001; 114: 4477-4483.
26. Evdokimova V, Tognon C, Ng T, Sorensen PH. Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 2009; 8: 2901-2906.
27. Hugo HJ, Pereira L, Suryadinata R, Drabsch Y, Gonda TJ, Gunasinghe NP et al. Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells. Breast Cancer Res 2013; 15: R113.
28. Akhurst RJ, Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol 2001; 11: S44-S51.
29. Oka M, Hamamoto Y, Okabe N. Evaluating system for predicting cancer return, Patent Number: CN100398663(C), granted on 02 July 2008.
30. Liu Y, Sanchez-Tillo E, Lu X, Huang L, Clem B, Telang S et al. Sequential inductions of the ZEB1 transcription factor caused by mutation of Rb and then Ras proteins are required for tumor initiation and progression. J Biol Chem 2013; 288: 11572-11580.
31. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
32. Jen KY, Song IY, Banta KL, Wu D, Mao JH, Balmain A. Sequential mutations in Notch1, Fbxw7, and Tp53 in radiation-induced mouse thymic lymphomas. Blood 2012; 119: 805-809.
33. Bienvenu T, Diebold B, Chelly J, Isidor B. Refining the phenotype associated with MEF2C point mutations. Neurogenetics 2013; 14: 71-75.
34. Novara F, Rizzo A, Bedini G, Girgenti V, Esposito S, Pantaleoni C et al. MEF2C deletions and mutations versus duplications: a clinical comparison. Eur J Med Genet 2013; 56: 260-265.
35. Yang M, Chen J, Su F, Yu B, Lin L, Liu Y et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer 2011; 10: 117.
36. Zhao JX, Yue WF, Zhu MJ, Du M. AMP-activated protein kinase regulates beta-catenin transcription via histone deacetylase 5. J Biol Chem 2011; 286: 16426-16434.
37. McGee SL, van Denderen BJ, Howlett KF, Mollica J, Schertzer JD, Kemp BE et al. AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5. Diabetes 2008; 57: 860-867.
38. Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res 2012; 14: R79.